阿托伐他汀在冠心病治疗中的抗炎作用分析

Analysis of Anti Inflammatory Effect of Atorvastatin in the Treatment of Coronary Heart Disease

目的分析和研究在冠心病患者治疗阶段服用阿托伐他汀所起到的抗炎效果。方法随机选择了2014年1月—2014年10月在该院接收冠心病治疗的80例患者作为研究对象,将其随机划分成对照组和实验组,每组40例患者。对照组患者给予常规内科治疗,而实验组患者在对照组的基础上又给予了20mg阿托伐他汀治疗,然后对两组患者的C反应蛋白、胆固醇、血浆白细胞介素-18、超敏C应蛋白、并发症以及消化道不良反应进行检测和记录。结果实验组患者的C反应蛋白(CRP)、血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和三酰甘油(TG)测试结果下降明显低于对照组,而高密度脂蛋白胆固醇(HDL-C)测试结果上升明显高于对照组,他们之间的差异具有统计学意义(P<0.05)。同时治疗后,对照组患者的IL-18和hs-CRP与治疗前无明显差异,不具有统计学意义(P>0.05),而实验组患者治疗后IL-18和hs-CRP明显低于治疗前;并且实验组患者脑卒中、心力衰竭、肝功能异常、心律失常等并发症的发生率和消化道不良反应发生率明显低于对照组,他们之间的差异具有统计学意义(P<0.05)。结论对冠心病患者采用阿托伐他汀治疗,不仅可以有效改善患者的各项检测指标,达到抗炎效果,而且还能降低并发症和不良反应的发生率,因此值得在临床上推广。

Objective To analyze and study taking anti-inflammatory effect of atorvastatin in the treatment of stage plays in pa-tients with coronary heart disease. Methods Chose 2014 January -2014 year in October in our hospital 80 cases receiving treat-ment for coronary artery diseasepatients as the research object, it will be randomly divided into experimental group and control group, each group of 40 cases. The control group were given routine Department of internal medicine treatment, while patients in the experimental group on the basis of the control groupwas given 20mg atorvastatin treatment, then the two groups of patients with C reactive protein, cholesterol, plasma interleukin -18, high sensitive C protein, complications andgastrointestinal adverse reaction for the detection and recording. Results The experimental group patients with C reactive protein （CRP）, serum total cholesterol （TC）, low densitylipoprotein cholesterol （LDL-C） and three triacylglycerol （TG） test results was significantly lower than the control group, and high density lipoprotein cholesterol （HDL-C） test resultsincreased significantly higher than that of the control group, statistically significant differences between them between the （P〈0.05）. At the same time after treatment, patients in the control group of IL-18 and hs-CRP before and after treatment no significant difference was not statistically significant （P〉0.05）, while the patients in the experimental group after the treatment of IL-18 and hs-CRP was significantly lower than that before treatment;and patients in the experimental group Nao Zuzhong, heart failure, liver dysfunction, arrhythmia and othercomplication rate and gas-trointestinal adverse the reaction was significantly lower than the control group, with statistically significant difference between them （P〈0.05）. Conclusion Atorvastatin treatment with atorvastatin on patients with coronary heart disease, not only can effectively improve the patients with the detection of indicators, to achieve anti-inflammatoryeffect, but also reduce the complications and the incidence rate of adverse reactions, so it is worth promoting in clinical practice.